EXJADE is the once-daily oral breakthrough that simplifies iron chelation.

Femara is an aromatase inhibitor approved as an oral, once-daily tablet to treat breast cancer in postmeno-
pausal women.

Targeted oncology drug that validates rational drug design based on an understanding of how certain cancer cells work.

Long-term maintenance therapy for acromegaly and the treatment of symptoms related to carcinoid syndrome and VIPomas.

A tyrosine kinase inhibitor for adult patients with chronic or accelerated phase PH+ CML resistant to at least one prior therapy.

Indicated for the prevention of skeletal related events from advanced malignancies involving bone and the treatment of tumour-
induced hyper-
calcaemia.